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arrest or apoptosis [3]. Among many possible targets,Targeting FOXO Kills Two Birds
there is little doubt that phospho-Akt has a critical rolewith One Stone in many human cancers, often as a consequence of
PTEN inactivation [4]. PTEN, both a lipid phosphatase
and a protein phosphatase, is frequently mutated in a
wide range of human malignancies, including glioma,
PTEN deficiency activates Akt signaling and results prostate and breast tumors, melanoma, squamous cell
in a variety of human malignancies. Encouragingly, carcinoma, and thyroid tumors [5, 6]. Animal models
recent studies demonstrate that small molecules can have shown that PTEN knockout is embryonic lethal and
regulate FOXO1a, an Akt target, to suppress tumor that heterozygous PTEN-depleted mice are prone to the
growth, and FOXO1a is therefore a promising antican- development of various cancers [7, 8]. Restoring PTEN
cer drug target. function in mutant PTEN-containing tumor cells by
expressing exogenous PTEN can largely reverse the
Molecular targeting of tumor-specific signal transduc- malignant phenotype. The main mechanism of cancer
tion pathways is a promising strategy for discovering development due to PTEN inactivation is constitutive
and developing novel potent anticancer drugs. Small- activation of Akt function. Akt is a kinase that has numer-
molecule libraries have been intensively screened for ous targets, many of which are important for regulating
compounds that block ligand-receptor interaction [1], the balance between cell survival and apoptosis [9, 10];
those that block signaling transduction pathways [2], such targets include MDM2, Bad, Bcl-2, CDK inhibitors,
caspase 9, and forkhead transcription factors such asand those that block master regulators of cell cycle
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FOXO1a, FOXO3a, and FOXO4. Phosphorylation of normal cells. Even if most of the screened compounds
do not end up in clinical use, they may still serve asthese targets by Akt activates or reduces their function
in favor of cell growth. Notably, Akt-mediated forkhead good tools for laboratory use to help us understand the
roles of their targets in tumorigenesis, and this mayphosphorylation leads to cytoplasmic retention and loss
of activation of transcription of pro-apoptotic genes possibly lead to the discovery of new members of the
pathway or better homologs for therapeutic purposes.such as Fas ligand [11] and cell cycle modulators [12,
13]. Currently, there is no specific anti-Akt drug in the Thus, the emergence of these PI3K/PTEN/Akt pathway
inhibitors may have great impact on efforts to studyclinic or in clinical trials, but there are preclinical data
implicating phospho-Akt as a prognostic marker and as signaling events and further development of anticancer
agents.an important pathogenic event in cancer [14]. Further-
more, there is a growing literature about the underlying It is worth remembering that the PI3K/PTEN/Akt path-
way forms a complicated network with other signalingmechanisms of Akt action with respect to cell survival
[4, 5, 10]. pathways that modulate cell survival and death, e.g.,
the MDM2/p53 pathway [2, 10, 17]. Akt phosphorylatesBased on the fact that Akt plays an important role in
tumor development, especially when PTEN is inacti- MDM2 and activates its E3 ubiquitin ligase activity. Con-
sequently, p53 is degraded more rapidly by MDM2 invated and phosphorylation by Akt leads to FOXO1 nu-
clear export, Kau et al [15] performed a cell-based, high- cells with activated Akt. Inhibition of Akt function by the
inhibitors may result in reduction of MDM2 activity andthroughput, genetic screen of three different libraries of
small molecules to look for effective inhibitors of the therefore an enhancement of p53 transcriptional activ-
ity. p53 can transcriptionally activate PTEN, which mayPI3K/PTEN/Akt pathway, which may, at least in part,
mimic PTEN function. For this analysis they used a further inhibit Akt activity. Therefore, inhibition of Akt
by the inhibitors may trigger a positive feedback withPTEN-null cell line that expresses exogenous FOXO1a
by adenovirus infection and treated the cells with com- perhaps additional anti-tumor effects. However, p53 is
frequently mutated in human tumors, as is PTEN to apounds from the libraries. Exogenous FOXO1a accumu-
lated in the cytoplasm as a result of phosphorylation by lesser extent. Fortunately, it may be much less frequent
that both tumor suppressors are deficient in the sameconstutively active Akt in the PTEN-null cells. As positive
controls, they employed widely used PI3K inhibitors to tumors. Screening for PTEN mimics or, broadly, PI3K/
Akt pathway inhibitors may complement the efforts fo-suppress Akt function and the nuclear export inhibitor
LMB to induce translocation of cytoplasmic FOXO1a to cusing on mutant p53 restoration [3, 18, 19]. It will be
of interest in the not-too-distant future to determine thethe nucleus. They screened more than 18,000 com-
pounds from the NCI structural diversity set, Chem- effects of the novel compounds in combination with
other agents in human tumors and animal models withBridge DiverSetE, and a small collection of NCI marine
extracts in an attempt to identify compounds that relo- defined genetic alterations. It may also be of interest to
investigate the effects of restoring nuclear expressioncalize FOXO1a to the nucleus in the PTEN-null cells. By
directly visualizing the subcellular localization of FOXO1a, of other Akt targets, such as p21 (WAF1/CIP1) [20], alone
and in combination with the FOXO1a targeting agents.they successfully identified 42 compounds with the abil-
ity to direct FOXO1a to the nucleus. The progress made by Kau et al. [15] toward identifying
a potential lead drug that targets a major pathway dereg-Because phosphorylation and subsequent localiza-
tion of FOXO1a is a downstream event in the PI3K/PTEN/ ulated in cancer represents an important milestone for
academic researchers and shows that it is possible toAkt pathway and reconstitution of forkhead activity is
sufficient to restore the induction of apoptosis in conduct unique and important drug discovery at an aca-
demic institution [21].PTEN-null cells, any step of the pathway blocked by the
compounds would show the same phenomenon. The
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known. Therefore, the exact target of the second cate-
gory and the mechanism by which members inhibit the Selected Reading
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In a recent paper, Hutter and Benner now appear toOrthogonal Base Pairs
have solved this problem [7]. 6-Amino-2-oxo-(1H) pyri-Continue to Evolve dine linked C3 to C1 of 2-deoxyribose is prone to epi-
merization through a mechanism initiated by proton-
ation of the furanose oxygen followed by furanose ring
opening coordinated with loss of the proton on N1. Re-
Recent developments in the design and construction closure leads to both the  and 
 epimers about C1.
of unusual analogs of the natural nucleic acid bases Hutter and Benner rationalized that the introduction of
have reached a milestone with the report (in this issue a strong electron withdrawing group at C5 would pre-
of Chemistry & Biology [1]) of a new orthogonal base vent the electron release required for ring opening. In-
pair that allows site-specific introduction of a photo- deed they have now demonstrated that the iso-C analog,
crosslinkable modified base into an RNA molecule by 6-amino-3-(2-deoxy-
-D-ribofuranosyl)-5-nitro-(1H)-
T7 RNA polymerase-mediated transcription of DNA pyridine-2-one is stable to epimerization under condi-
containing the base-pairing partner. tions that one typically encounters during synthesis and
manipulation of nucleoside triphosphates and oligonu-
One of the more interesting challenges in modified base cleotides. One can expect that this work will soon be
design has been the creation of new orthogonal base extended to polymerase-mediated nucleic acid repli-
pairs that would function as substrates for enzymes cation.
involved in the synthesis and processing of nucleic acids As an alternative to orthogonal hydrogen bonding nu-
and would thereby provide a means for the expansion cleoside analogs, Kool and coworkers have been explor-
of the genetic code [2]. The earliest concerted effort to ing nonhydrogen-bonding isosteres of the natural bases
expand the genetic code and create new base pairs [8]. A critical finding from this laboratory was that the
came from the laboratory of Benner and coworkers. In hydrophobic shape-complementary purine-pyrimidine
studies initiated during the 1980s, a series of putative analogs preferentially pair with one another [9, 10]. Oth-
base pairs containing alternative orthogonal hydrogen ers variations on this theme have uncovered a number
bonding patterns were designed and synthesized [3, 4]. of interesting new base pairs. Most noteworthy has been
Although the initial results with the isoC-isoG base pair the effort by Romesberg, Schultz, and coworkers, who
looked promising, subsequent work showed that isoC have focused on the theme of creating unique hydropho-
was unstable in aqueous solution [5]. Furthermore, dif- bic base analogs with significant preference for self-
ferent polymerases show a broad range of specificity pairing in nucleic acid duplexes [11].
and recognition characteristics with these bases as tem- Recently Hirao and coworkers reported a strategy for
plate and as triphosphate substrates. In subsequent the construction of orthogonal base pairs that depend
years the Benner laboratory continued to explore new more on molding complementary shapes rather than
variations on alternative H-bonding pattern modified hydrogen bonding pattern [12, 13]. They have found
bases. These studies included C-linked pyrimidine ana- pairing specificity between a purine bearing a nonhydro-
logs [4, 6], which although optimal from the standpoint gen-bonding substituent on C6 of a purine and a pyridine
of alternative H-bonding patterns, proved to be unstable C-nucleoside that mimics a pyrimidine nucleoside minus
the C4 amino or oxo group. This pairing is illustrated intoward epimerization at C1.
